Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

Biocon Biologics secures multiple market access agreements in the US for its biosimilar, Yesintek, for treating Crohn's ...

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis ...